On August 25, the (36th) China Pharmaceutical Industry Information Conference 2019 and the 3rd China (Lianyungang) International Conference on Pharmaceutical Technology held by China National Pharmaceutical Industry Information Center kicked off in Lianyungang. Government leaders, industry leaders and industry elites gathered in the “Drug Port” to identify the industrial development trend and conduct valuable exploration for the industry's leap-forward development. During the conference, “China’s Best Industrial Enterprises in Pharmaceutical R&D Pipeline 2019” were officially announced, and Hansoh Pharma was once again on the list with its outstanding performance in scientific research and development, which was also its ranking among the top three for the third consecutive year after 2017 and 2018.
“China’s Best Industrial Enterprises in Pharmaceutical R&D Pipeline 2019” were selected by experts organized by China National Pharmaceutical Industry Information Center in a fair, objective and authoritative manner, and 25 enterprises were selected nationwide. The aim is to track the domestic and international R&D dynamics in real time, explore the greatest potential in the domestic pharmaceutical R&D field, carry out in-depth exploration of the context of industry changes, select the future rising stars with the highest value of investment in China's pharmaceutical industry, and identify the leaders in the future development of China's pharmaceutical industry, so as to promote the more healthy and rapid development of the entire industry through a first pilot and then roll-out approach.
Hansoh Pharma is committed to solving the unsatisfied clinical demand in major disease fields through technological innovation. Over the years, it has continuously increased its investment in innovation and R&D. It has established two R&D centers in Shanghai and Lianyungang, and set up a scientific and complete R&D system. At present, the Company has successfully launched two innovative drugs. The Company's independently developed Fulaimei(polyethylene glycol loxenatide injection) was approved for marketing in May 2019, which is the world's first PEGylated long-acting GLP-1 drug and requires only one injection a week; and two innovative drugs, flumatinib mesylate and osimertinib mesylate, have been included in the priority review procedure and will be available on the market soon.
In the future, Hansoh Pharma will accelerate the pace of technological innovation, lead the industry to transform and upgrade, create excellence in pharmaceuticals, enhance innovation in China, and contribute to the grand plan of “Healthy China 2030”.
